These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Chronic bullous disease of childhood--aspects of management. Rogers M; Bartlett B; Walder B; Cains G Australas J Dermatol; 1982 Aug; 23(2):62-9. PubMed ID: 6758754 [No Abstract] [Full Text] [Related]
5. Very late recovery of dapsone-induced methemoglobinemia. Wieringa A; Bethlehem C; Hoogendoorn M; van der Maten J; van Roon EN Clin Toxicol (Phila); 2014 Jan; 52(1):80-1. PubMed ID: 24308869 [No Abstract] [Full Text] [Related]
6. Sulfones and sulfonamides in dermatology today. Lang PG J Am Acad Dermatol; 1979 Dec; 1(6):479-92. PubMed ID: 528697 [TBL] [Abstract][Full Text] [Related]
7. Acute Generalized Exanthematous Pustulosis (AGEP) due to dapsone in a patient with leprosy. Narasimharao P; Pratap DV; Suneetha S Lepr Rev; 2009 Mar; 80(1):81-4. PubMed ID: 19472855 [No Abstract] [Full Text] [Related]
8. Dapsone-induced methemoglobinemia in leprosy patients. Kaur I; Mehta M; Agnihotri N; Dogra S; Ganguly NK Int J Lepr Other Mycobact Dis; 2001 Sep; 69(3):247-9. PubMed ID: 11875770 [No Abstract] [Full Text] [Related]
9. Bullous pemphigoid responding to sulfapyridine and the sulfones. Person JR; Rogers RS Arch Dermatol; 1977 May; 113(5):610-5. PubMed ID: 324403 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human skin proteinases by chloroquine, dapsone and sulfapyridine. Fräki JE; Hopsu-Havu VK Arch Dermatol Res (1975); 1977 Jul; 259(1):113-5. PubMed ID: 900989 [No Abstract] [Full Text] [Related]
11. Very late relapse of dapsone-induced methaemoglobinemia. Moulis G; Bagheri H; Saint Martory J; Bernard P; Montastruc JL Eur J Clin Pharmacol; 2010 Jun; 66(6):645-6. PubMed ID: 20229100 [No Abstract] [Full Text] [Related]
13. Psychiatric reaction to dapsone and sulfapyridine. Fine JD; Katz SI; Donahue MJ; Hendricks AA J Am Acad Dermatol; 1983 Aug; 9(2):274-5. PubMed ID: 6886118 [No Abstract] [Full Text] [Related]
14. Dapsone in the management of autoimmune bullous diseases. Piette EW; Werth VP Immunol Allergy Clin North Am; 2012 May; 32(2):317-22, vii. PubMed ID: 22560144 [TBL] [Abstract][Full Text] [Related]
15. [Salazopyrine]. de Longraye J; Brard M Soins; 1981 Oct; 26(19):27-8. PubMed ID: 6914024 [No Abstract] [Full Text] [Related]
16. Sulfonamides and sulfones in dermatologic therapy. Bernstein JE; Lorincz AL Int J Dermatol; 1981 Mar; 20(2):81-8. PubMed ID: 7012050 [No Abstract] [Full Text] [Related]
17. Dapsone as first line therapy for bullous pemphigoid. Venning VA; Millard PR; Wojnarowska F Br J Dermatol; 1989 Jan; 120(1):83-92. PubMed ID: 2700666 [TBL] [Abstract][Full Text] [Related]
18. Dapsone-induced photodermatitis in a patient with linear IgA dermatosis. Stöckel S; Meurer M; Wozel G Eur J Dermatol; 2001; 11(1):50-3. PubMed ID: 11174140 [TBL] [Abstract][Full Text] [Related]
19. Patient compliance with dapsone administration in leprosy. Huikeshoven H Int J Lepr Other Mycobact Dis; 1981 Jun; 49(2):228-58. PubMed ID: 7024150 [No Abstract] [Full Text] [Related]
20. Dapsone for the treatment of bullous pemphigoid. Piamphongsant T Asian Pac J Allergy Immunol; 1983 Jun; 1(1):19-21. PubMed ID: 6398078 [No Abstract] [Full Text] [Related] [Next] [New Search]